Welcome to the European Consortium for Emergency Contraception (ECEC)
Founded in 2012, ECEC works to expand knowledge about and access to Emergency Contraception (EC) in Europe, and promotes the standardization of EC service delivery to ensure equitable access across the region. Since 2020, ECEC also works globally to advance access to EC.
EC is the only contraceptive method that can be used after sex, and it provides women with an additional opportunity to prevent a pregnancy.
Through this website, we hope to contribute to generating and sharing knowledge of EC in Europe and globally. Your contributions are essential to helping us achieve this goal, and we encourage you to share EC information about your country by writing to us at ecec [at] eeirh [dot] org.
Go directly to country-by-country information on EC access
Go directly to the online EC counseling tool (The EC wheel)
Latest News
ECEC at ESCRH 18 Congress – Belgrade
April 2026. We’re pleased to share that ECEC will be attending the European Society of Contraception and Reproductive Health (ESCRH) Congress in Belgrade on May 6-9. Join us for a dedicated session on Emergency Contraception: Thursday, 7 May 2026 Block 4 Emergency Contraception Chairs: Kristina Gemzell (Sweden) & Aleksandar Jurisic (Serbia) We look forward to…
Japan launches second non-prescription emergency contraceptive pill
April 2026 — A new levonorgestrel-based emergency contraceptive (EC) pill, Lesoeru 72, has been approved and launched in Japan, becoming the second brand available without a prescription in the country. According to Fuji Pharma Co., Ltd., approval was granted on 10 February 2026, with distribution starting in March. Lesoeru 72 is classified as a pharmaceutical…
Argentina: First UPA emergency contraceptive pill introduced
April 2026 — A ulipristal acetate (UPA)-based emergency contraceptive (EC) pill is now available in Argentina. Since March 2026, Efectiva 30, manufactured by Laboratorios CASASCO, has been distributed in pharmacies nationwide. The product is available by prescription only and is expected to retail at approximately USD 12, with lower prices anticipated through union-run health insurance…